Trulieve Cannabis stock
TRLVNYSETrulieve Cannabis Corp., HealthcareISIN US89790E1064
47Score 47 out of 100, Weak
Price and trend
77 / 100
Price history
+62% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 25% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 14% below its 52-week high. Largest decline in 8 years: 94% (March 2021 to April 2025).
Chart figures for advanced users
- SMA 50$11.16
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.76
- The lowest closing price of the last twelve months.
- Resistance$13.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Trulieve Cannabis Corp. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $2.15B, is number 50 of 77 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.01B (down 14.7%) and adjusted earnings per share of −$1.82.
- MEQIRI Score 47 out of 100 (Weak): rank 426 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Volatile share priceVolatility 109% a year over the last 12 months.Stability 55
- Loss-makingLoss of $445.68M over the last 12 months.Fundamentals 10
- Interest barely coveredOperating profit covers interest only 2.4 times.Stability 55
Its standout strengths are momentum and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 20.1% on the same quarter a year earlier.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 60%, operating 13%, net −10%. Last 12 months: net −41%.
Debt & balance sheet
Fiscal 2025Debt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 5 Nov 2026EPS reported $0.09 (expected $0.09)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.820.0%
- Revenue
- $1.01B0.0%
- Earnings per share
- $0.580.0%
- Revenue
- $936.36M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +0.9%Expected 2026 operating cash flow lowered to at least $225 million from $250 million due to deconsolidation; capital expenditures raised to $95 million from $85 million.
“For the full year 2026, we anticipate operating cash flow of at least $225 million, reduced from $250 million to reflect the impact of deconsolidation. With increased investment in growth markets to meet demand, capital expenditures are now expected to be $95 million, up from $85 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $14.66M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Rivers Kim A.Sale
26 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 136,811
- Price
- $8.76
- Value
- $1.2M
- Rivers Kim A.Sale
25 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 300,000
- Price
- $8.17
- Value
- $2.45M
- Rivers Kim A.Sale
24 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 400,000
- Price
- $8.17
- Value
- $3.27M
Show 4 more
- Rivers Kim A.Sale
23 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 380,000
- Price
- $8.47
- Value
- $3.22M
- Rivers Kim A.Sale
22 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 204,815
- Price
- $9.35
- Value
- $1.92M
- Rivers Kim A.Sale
18 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 139,846
- Price
- $9.46
- Value
- $1.32M
- Rivers Kim A.Sale
17 Jun 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 137,535
- Price
- $9.36
- Value
- $1.29M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Trulieve Cannabis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- HUTCHMED (China)HCM $2.65B45
- AlmirallALM.MC $2.6B45
- Regencell Bioscience HoldingsRGC $2.54B31
- PerrigoPRGO $2.25B47
- FagronFAGR.BR $1.97B70
- Dermapharm HoldingDMP.DE $1.92B63
- Eton PharmaceuticalsETON $1.77B70
- Faes FarmaFAE.MC $1.72B70
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.